Financials data is unavailable for this security.
View more
Year on year BioRegenx Inc 's revenues fell -47.25% from 42.16k to 22.24k. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a loss of 78.31k to a larger loss of 571.17k.
Gross margin | 74.90% |
---|---|
Net profit margin | -114.67% |
Operating margin | -102.97% |
Return on assets | -7.07% |
---|---|
Return on equity | -8.64% |
Return on investment | -8.46% |
More ▼
Cash flow in USDView more
In 2023, cash reserves at BioRegenx Inc fell by 680.00. Cash Flow from Financing totalled 12.67k or 56.97% of revenues. In addition the company used 13.35k for operations while cash from investing was breakeven.
Cash flow per share | -0.0013 |
---|---|
Price/Cash flow per share | -- |
Book value per share | 0.0178 |
---|---|
Tangible book value per share | -0.0016 |
More ▼
Balance sheet in USDView more
Current ratio | 0.2766 |
---|---|
Quick ratio | 0.1547 |
Total debt/total equity | 0.1083 |
---|---|
Total debt/total capital | 0.0977 |
More ▼